Skip to main content

OncoCyte Raises $10M in Private Placement

NEW YORK (GenomeWeb) – OncoCyte announced on Wednesday that it has closed a $10 million private placement with two unnamed existing investors.

According to OncoCyte, the investors agreed to buy 7,936,508 shares of the company's common stock at $1.26 per share. OncoCyte said that it has already received $8 million from the stock sale and that one investor has committed to purchasing $2 million worth of additional shares before April 30.

During early morning trading on Thursday, shares of OncoCyte were trading up nearly 2 percent at $1.325.

OncoCyte intends to the use the proceeds of the placement to continue development of its liquid biopsy diagnostic tests for early cancer detection, for complementary acquisitions, and for working capital and other general corporate purposes.

In November, OncoCyte disclosed that the market launch of its lung cancer diagnostic DetermaVu, which would be the firm's first commercialized product, had been delayed due to technical issues during a clinical validation study. It also reported ending the third quarter of 2017 with cash and cash equivalents totaling $11 million.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.